Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$0.91 -2.3%	$0.86	$0.55 ▼ $1.66	$120.98M	0.9	749,517 shs	401,131 shs
GNLX Genelux	$3.08 -8.9%	$2.79	$1.60 ▼ $5.89	$127.63M	-0.34	172,001 shs	212,952 shs
KYTX Kyverna Therapeutics	$3.82 -13.0%	$2.86	$1.78 ▼ $11.40	$189.95M	2.95	387,090 shs	462,640 shs
NRSN NeuroSense Therapeutics	$1.98 -1.0%	$1.82	$0.51 ▼ $2.60	$27.33M	1.66	258,620 shs	204,618 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-2.33%	+7.98%	+10.15%	+51.21%	-34.66%
GNLX Genelux	-8.88%	-11.49%	+0.65%	+19.84%	+17.56%
KYTX Kyverna Therapeutics	-12.98%	+35.46%	+18.63%	+108.74%	-61.45%
NRSN NeuroSense Therapeutics	-1.00%	-5.71%	-16.81%	+92.05%	+114.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATOS Atossa Genetics	3.1457 of 5 stars	3.7	4.0	3.8	1.7	0.0
GNLX Genelux	1.2006 of 5 stars	3.6	0.0	2.6	0.0	0.0
KYTX Kyverna Therapeutics	1.9944 of 5 stars	3.6	2.0	2.6	0.0	0.6
NRSN NeuroSense Therapeutics	2.4602 of 5 stars	3.5	4.0	1.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	3.33	Buy	$6.17	574.10% Upside
GNLX Genelux	3.20	Buy	$17.75	476.30% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	384.29% Upside
NRSN NeuroSense Therapeutics	3.00	Buy	$14.00	607.07% Upside

Current Analyst Ratings Breakdown

Latest NRSN, KYTX, GNLX, and ATOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/6/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.25 ➝ $7.50
6/5/2025	ATOS Atossa Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$4.00
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/12/2025	NRSN NeuroSense Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
5/8/2025	GNLX Genelux	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Speculative Buy ➝ Speculative Buy	$25.00 ➝ $23.00
4/21/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.25

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$0.57 per share	N/A
GNLX Genelux	$10K	11,630.08	N/A	N/A	$0.76 per share	4.05
KYTX Kyverna Therapeutics	$7.03M	23.49	N/A	N/A	$6.17 per share	0.62
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	$0.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$25.50M	-$0.21	N/A	N/A	N/A	N/A	-33.90%	-31.53%	8/11/2025 (Estimated)
GNLX Genelux	-$29.87M	-$0.88	N/A	N/A	N/A	N/A	-93.04%	-74.17%	8/13/2025 (Estimated)
KYTX Kyverna Therapeutics	-$127.48M	-$3.38	N/A	N/A	N/A	N/A	-51.66%	-45.92%	8/11/2025 (Estimated)
NRSN NeuroSense Therapeutics	-$10.21M	-$0.54	N/A	∞	N/A	N/A	N/A	-445.40%	N/A

Latest NRSN, KYTX, GNLX, and ATOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	GNLX Genelux	-$0.22	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ATOS Atossa Genetics	-$0.06	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	KYTX Kyverna Therapeutics	-$1.00	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ATOS Atossa Genetics	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/8/2025	Q1 2025	GNLX Genelux	-$0.24	-$0.21	+$0.03	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	12.67	12.67
GNLX Genelux	N/A	4.67	4.67
KYTX Kyverna Therapeutics	N/A	7.44	7.44
NRSN NeuroSense Therapeutics	N/A	2.21	2.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
GNLX Genelux	37.33%
KYTX Kyverna Therapeutics	18.08%
NRSN NeuroSense Therapeutics	1.04%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	8.70%
GNLX Genelux	9.30%
KYTX Kyverna Therapeutics	N/A
NRSN NeuroSense Therapeutics	27.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	8	129.17 million	117.93 million	Optionable
GNLX Genelux	10	37.76 million	34.23 million	Not Optionable
KYTX Kyverna Therapeutics	96	43.22 million	N/A	Optionable
NRSN NeuroSense Therapeutics	10	13.67 million	9.92 million	Not Optionable

NRSN, KYTX, GNLX, and ATOS Headlines

Recent News About These Companies

NeuroSense Therapeutics (NASDAQ:NRSN) Receives "Buy" Rating from D. Boral Capital

July 13 at 2:35 AM | americanbankingnews.com

NeuroSense Therapeutics Releases Q2 2025 Corporate Update

July 10, 2025 | tipranks.com

Neurosense Therapeutics Ltd News (NRSN) - Investing.com

July 2, 2025 | investing.com

NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval

June 26, 2025 | tipranks.com

Top Nasdaq Companies by Market Cap Ranked by Kalkine

June 7, 2025 | kalkinemedia.comK

Neurosense, awaiting Canada approval, scales PrimeC production

May 15, 2025 | alsnewstoday.comA

D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation

May 14, 2025 | msn.com

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025 | benzinga.com

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025 | prnewswire.com

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership

April 24, 2025 | tipranks.com

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

April 24, 2025 | prnewswire.com

NeuroSense Therapeutics Presents Promising Phase 2b Data on PrimeC for ALS at AAN Meeting

April 10, 2025 | sohu.comS

NeuroSense Therapeutics Reports Year-End 2024 Financial Results and Provides Business Updates

April 10, 2025 | sohu.comS

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

April 9, 2025 | prnewswire.com

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

April 7, 2025 | prnewswire.com

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

April 4, 2025 | prnewswire.com

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

March 20, 2025 | businesswire.com

NeuroSense Advances PrimeC Commercialization in Canada

March 19, 2025 | tipranks.com

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

March 17, 2025 | businesswire.com

Life Saving Innovation in Neurodegenerative Disease Treatment: An Interview with Alon Ben-Noon, CEO & Founder of NeuroSense Therapeutics

March 12, 2025 | techbullion.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, KYTX, GNLX, and ATOS Company Descriptions

Atossa Genetics NASDAQ:ATOS

$0.91 -0.02 (-2.33%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$0.91 -0.01 (-0.74%)

As of 07:00 AM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Genelux NASDAQ:GNLX

$3.08 -0.30 (-8.88%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$3.25 +0.17 (+5.49%)

As of 07:00 AM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Kyverna Therapeutics NASDAQ:KYTX

$3.82 -0.57 (-12.98%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$3.87 +0.05 (+1.34%)

As of 07:08 AM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

NeuroSense Therapeutics NASDAQ:NRSN

$1.98 -0.02 (-1.00%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$1.96 -0.02 (-1.01%)

As of 07:00 AM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time